Stem cell therapy: A promising treatment for COVID-19

Table 1 Characteristics of included stem cell studies of Coronavirus disease 2019

Ref.	Disease	Treatment	n	Results
Leng et al[14], 2020	COVID-19 pneumonia	MSCs	7	Improve outcome without adverse effects
Chen et al[52], 2020	Severe COVID-19 pneumonia	MSCs	25	All patients gained clinical improvement and 64% gained chest CT improvement
Liang et al[53], 2020	Severe COVID-19 pneumonia	UC-MSCs	1	Most of the laboratory indexes and CT images showed remission without side effects
Shu et al[55], 2020	Severe COVID-19 pneumonia	UC-MSCs	12	The UC-MSC treatment group had shorter clinical improvement time, reduced CRP and IL-6 levels, and no mortality
Meng et al[56], 2020	Moderate and serve COVID-19 pneumonia	UC-MSCs	9	No serious adverse events were observed and all the patients recovered and were discharged
Sánchez-Guijo et al[57], 2020	Severe COVID-19 pneumonia	AD-MSCs	13	70% of patients had clinical improvement and no adverse events were related to the therapy
Tang et al[58], 2020	Severe COVID-19 pneumonia	MB-MSCs	2	Bilateral pulmonary exudation had been absorbed and SaO2 and PO2 were also improved

COVID-19: Coronavirus disease 2019; MSCs: Mesenchymal stem cells; UC-MSCs: Umbilical cord-derived MSCs; AD-MSCs: Adipose tissue-derived MSCs; MB-MSCs: Menstrual blood-derived MSCs; CT: Computed tomography.